Prahsant Kumar 
When it comes to conducting clinical trials and managing regulatory affairs, many life sciences companies consider partnering with a Contract Research Organization (CRO). CROs offer specialized expertise, infrastructure, and resources that can help streamline complex drug development processes. However, this collaboration also comes with certain trade-offs. At FDAMap, we believe it’s essential for sponsors to … Read more
Antibacterial therapies targeting serious infections in patients with limited or no therapeutic options are hard to develop for scientific, logistical, and financial reasons. FDA’s latest guidance describes the FDA’s expectations for developers of antibiotics for patients with an unmet medical need for a serious bacterial infection. The guidance articulates a science- and risk-based framework for … Read more
Cyber threats can present a direct risk to patient lives. The FDA’s updated 2025 guidance on cybersecurity in medical devices emphasizes, with templates and examples, the importance of cybersecurity considerations from the first line of code. The new guidance adds on to previous guidances to outline the FDA’s expectations from what manufacturers must do to … Read more
Is the FDA protecting American patients—or playing politics with science? Informed consent rules already safeguard the use and export of human biological materials, yet the agency’s new halt on international cell engineering trials suggests a politically charged narrative that paints foreign labs as threats to U.S. security, rather than collaborators in global innovation. In a … Read more
What happens when the pillars of America’s scientific and regulatory powerhouses, the FDA and NIH, are shaken to their core by political overreach? Amid the chaos and cuts, a surprising opportunity is emerging: the rise of a bold, independent R&D movement that could transform the future of medicine. In a one-two punch that has rocked … Read more
The FDA just called out another non-IND clinical trial with a supplement claiming medical benefits. An FDA inspection revealed that the sponsor of a Relaxium® Sleep study bypassed critical regulatory steps, raising serious concerns about participant safety and data integrity in unapproved clinical trials. In a Warning Letter to the American Behavioral Research Institute (ABRI), … Read more
The FDA has officially launched a new review voucher, the Commissioner’s National Priority Voucher (CNPV), an initiative to accelerate the review timeline for new drugs and biologics. The program promises to shorten FDA review time from the current 6–12 months (under PDUFA timelines) to as little as 1–2 months. Targeting products that align with U.S. … Read more
The investigation by an independent non-government group raises serious and important questions about the FDA’s drug approval processes. It rightfully draws attention to systemic flaws, especially the increasing reliance on surrogate endpoints, the lack of timely confirmatory studies, and the real harms patients face when exposed to ineffective or dangerous drugs. However, while the facts … Read more
The National Institutes of Health (NIH) is charting an ambitious course into the future of biomedical science with its proposed institute-wide AI strategy. Framing AI as a cornerstone of future scientific advancement, the agency envisions a world where artificial intelligence evolves from simple analytics tools into fully autonomous, self-documenting AI “beings.” While the vision is … Read more
Last April, in what can only be described as a mic-drop moment for clinical laboratories, a federal judge in Texas struck down the FDA’s bold (and arguably baffling) move to reclassify laboratory-developed tests (LDTs) as medical devices. It was a legal slapdown decades in the making—and the FDA didn’t even bother to appeal. The deadline … Read more
